Rejected from Nature Chemical Biology? The 6 Best Journals to Submit Next

Source: Clarivate JCR 2024, journal author guidelines and publishing-options pages (accessed June 2026). APCs are list prices for the gold open-access route and change annually.

Cell Chemical Biology

Cell Chemical Biology is the closest peer to Nature Chemical Biology in both mission and prestige. It is the Cell Press venue for work that genuinely integrates chemistry and biology, which means a paper rejected from Nature Chemical Biology on quality rather than scope often fits here without reframing. The editorial culture rewards the same thing: chemistry and biology that need each other.

If the integration was real but the conceptual advance was judged a step short of the Nature Chemical Biology bar, this is the first place to look.

Best for: Genuinely integrated chemical biology where neither half is decorative, and the paper is strong but not field-defining.

ACS Chemical Biology

ACS Chemical Biology serves the broad chemical biology community with a lower selectivity bar than the two flagship interface journals. The forum is explicitly built to connect chemists and biologists, so interface work that Nature Chemical Biology called "insufficient general interest" can find an engaged specialist readership here. The JIF (~3.6) is lower, but for chemical-probe development, activity-based profiling, and mechanism-of-action studies, it is a respected and realistic home.

Best for: Solid interface work, chemical probes, and mechanism studies that did not clear the top-tier novelty bar but belong squarely at the interface.

Nature Chemistry

If the honest answer is that your paper is chemistry first, with biology as the application, Nature Chemistry is the better Nature Portfolio target. It is highly selective (around 9% acceptance) and wants the chemistry itself to be the contribution: new reactivity, new structure, new physical-chemical insight. A paper that Nature Chemical Biology redirected because "the biology is thin" may be exactly what Nature Chemistry wants, provided the chemistry is genuinely novel.

Best for: Chemistry-led papers where the molecular or mechanistic advance is the story and the biology is the demonstration.

JACS

The Journal of the American Chemical Society is the broadest top-tier chemistry venue and the natural move for a chemistry-led paper that needs broad chemical interest rather than interface framing. JACS (IF ~15.6, ~15-18% acceptance) publishes across every subdiscipline and turns decisions around faster than most Nature Portfolio titles. If Nature Chemical Biology's verdict was effectively "this is good chemistry but not chemical biology," JACS evaluates it on chemistry alone. See our rejected from JACS guide for the chemistry-flagship cascade beyond it.

Best for: Chemistry-led work with broad significance to chemists, where interface framing was the misfit rather than the science.

Nature Communications

Nature Communications is the broad-scope Nature Portfolio fallback. It covers all natural science with an ~8% acceptance rate, and it does not require the cross-field significance bar of Nature itself, only a significant advance within a field. For interface work whose contribution is real but does not slot cleanly into a chemistry-versus-biology box, Nature Communications can be a better fit than forcing the paper back into a discipline-specific venue.

Best for: Interdisciplinary work with a clear advance that resists a single-discipline label, where breadth of audience matters.

Communications Chemistry

Communications Chemistry is the Nature Portfolio cascade for chemistry papers, and it is built to receive transfers. If your paper was reviewed at Nature Chemical Biology, the editors can offer a transfer here through the Nature Portfolio service with the referee reports attached, which is the single biggest time saver after a post-review rejection. The selectivity is more moderate (IF ~6), and the receiving editors can act on the existing reviews rather than restarting the clock.

Best for: Reviewed papers offered a transfer, and sound chemistry that benefits from carrying its referee reports forward.

Nature Chemical Biology sits inside the Nature Portfolio, so your next move can route through an in-house transfer rather than a cold submission. The decision turns on whether the rejection was scope or quality, and on which half of the interface led the paper.

Source: Manusights editorial routing logic, derived from Nature Chemical Biology and Nature Portfolio author guidelines (accessed June 2026).

Desk-rejected for scope? No reviews exist yet, so you are choosing a fresh target, not transferring. Decide which half was the real contribution. Chemistry-led goes to Nature Chemistry or JACS; integrated-but-narrower goes to Cell Chemical Biology or ACS Chemical Biology; broad-science goes to Nature Communications.

Rejected after review with a transfer offer? Take the transfer seriously. The Nature Portfolio transfer service, accessed through the manuscript tracking system at Nature Portfolio journal page, moves your manuscript and the referee reports together to Communications Chemistry (chemistry-led) or Communications Biology (biology-led). The receiving editor builds on the existing reviews, which is faster and reuses the work the referees already did.

A transfer offer is the editors signaling the science is sound but the venue was wrong. Before you transfer or resubmit, recompress the paper to the target format: a Nature Chemical Biology Article caps the main text at 4,500 words with a 150-word abstract, and the receiving journals have their own limits.

Rejected after review with no transfer offer? The reviewers found something fixable. Address every comment, then submit to the best-fit venue from the table above. The same gaps will surface at any peer-reviewed journal, so fix the science first and choose the journal second.

In our pre-submission review work with Nature Chemical Biology submissions, four patterns generate the most consistent desk rejections worth knowing before you resubmit. Each is testable against your own manuscript, and each maps to a specific fix.

Chemistry-led paper with biology bolted on. This is the dominant pattern we see in Nature Chemical Biology submissions. The core advance is a new molecule, reaction, or material, and a cell assay or animal experiment is appended in the last figure to argue biological relevance. The editors read this as a chemistry paper, not a chemical biology paper, because the biology does not change what the chemistry means. The test: remove the biology figures.

If the paper is still complete and the central claim survives, the biology was decorative, and Nature Chemistry or JACS is the better target than a second interface journal.

Biology-led paper where the chemistry is a purchased reagent. The mirror image. The contribution is a biological finding, and the "chemistry" is a commercial probe or a standard labeling kit used as a tool rather than developed as a contribution. Nature Chemical Biology wants the chemistry to be load-bearing, so a paper whose molecular component could be swapped for any equivalent reagent reads as biology with a chemical accessory.

The test: if the chemical tool is off-the-shelf and interchangeable, the paper belongs in a biology specialty journal, not at the interface.

Conceptual advance that optimizes rather than opens. Even genuinely integrated work is desk-rejected when the advance extends a known approach rather than opening a new avenue. We see this in manuscripts that apply an established chemical-biology method to a new target or system: competent, useful, and incremental by the journal's standard.

The journal explicitly seeks advances likely to open innovative avenues, so the test is whether your abstract claims a new capability or a new application of an existing one. Cell Chemical Biology and ACS Chemical Biology tolerate the latter; Nature Chemical Biology does not.

Characterization and controls insufficient to support the molecular claim. When a paper does clear the scope bar, the most common reviewer-stage failure is incomplete characterization of new compounds or missing controls for the biological readout. Nature Chemical Biology requires full structure, synthesis, and characterization for new compounds integral to the conclusions, and reviewers flag missing dose-response controls, absent specificity experiments, or activity attributed to a probe without confirming the probe is doing what is claimed.

The test: every molecular claim should have a control that would fail if the claim were wrong. If it does not, fix it before any resubmission, because Cell Chemical Biology and ACS Chemical Biology hold the same characterization standard.

These four patterns account for most of what we see fall short before review. The first two are scope problems that change which journal you target. The last two are quality problems that you fix before you target any journal.

Evidence basis: we reviewed Nature Chemical Biology's current aims, scope, and submission guidelines (accessed June 2026) alongside our internal anonymized pre-submission corpus for chemistry-biology-interface manuscripts. The named failure patterns above reflect what we consistently observe before submission; the metrics in the table reflect publicly documented venue facts, not per-submission claims.

Don't just resubmit the same file down the ladder. A scope rejection means you picked the wrong venue, and the honest fix is to diagnose which half of the interface your paper leads with before choosing the next target, not to resubmit identical text to a slightly less selective journal. Knowing when to walk away from a venue and do real work instead is the hard part.

A quality rejection means real work is required. If reviewers flagged thin characterization, a missing control, or a mechanism asserted without direct evidence, those gaps will reappear at every peer-reviewed journal, including the less selective ones. The same characterization standard that sank you at Nature Chemical Biology applies at Cell Chemical Biology and ACS Chemical Biology. Sometimes the right move is to do the missing experiments rather than to keep submitting; a faster journal does not forgive missing data, it just finds it faster.

If you were offered a transfer and the science is sound, the transfer is usually the better path than a cold submission elsewhere, because it preserves the reviewers' work. Weigh the receiving journal's prestige against the months a fresh review cycle would cost.